SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that effective March 24, 2011, PURE completed its reincorporation in the State of Delaware by merging into a wholly-owned Delaware subsidiary. The reincorporation was approved by the shareholders of PURE at the annual meeting of shareholders held on January 19, 2011, and adjourned and continued on February 10, 2011. The Company’s name has changed from PURE Bioscience to PURE Bioscience, Inc., and its CUSIP number has changed to 74621T 100. The Company’s common stock will continue to trade on the NASDAQ Capital Market under the ticker symbol “PURE.”
